De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer
Yiyin Ma, Dedian Chen, Sheng Huang · 2026
Read De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer by Yiyin Ma, Dedian Chen, Sheng Huang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13595470.txt.
Description
Yiyin Ma, Dedian Chen, and Sheng Huang review efforts to safely give less treatment to patients with early HER2-positive breast cancer. The subtype's outlook has improved so much that overtreatment is now a real concern. Their 2026 article focuses on therapy given before surgery, where response can be watched directly.
Strategies under study include shortening the course of HER2-targeted drugs and trimming the chemotherapy backbone. The central problem is choosing who can safely receive less. Scans that measure tumor metabolism or volume may flag the right patients. So may blood tests for circulating tumor DNA and other biomarkers. Those patients' cancers melt away on targeted therapy alone. The authors frame de-escalation as a matching problem, pairing lighter regimens with the tumors most likely to answer them.
Catalog record
| CREATOR | Yiyin Ma, Dedian Chen, Sheng Huang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |